Ozempic vs Wegovy
Identical molecule, different licence, different maximum dose — and that last difference is the one that decides what your insurance pays.
Key takeaways
- Ozempic and Wegovy are the same drug. Both are semaglutide, from the same manufacturer.
- They differ in what they are licensed to treat and how high the dose goes: Ozempic for type 2 diabetes up to 2 mg, Wegovy for weight management up to 2.4 mg.
- That difference is not cosmetic. It decides which one insurance will cover, and covering the "wrong" one is the single most common reason people end up paying full price.
- Prescribing Ozempic purely for weight loss is off-label — legal, common, and worth understanding before you assume it is equivalent.
- The weight-loss trial evidence, and the SELECT cardiovascular trial, were run at 2.4 mg — the Wegovy dose.
The same molecule
There is no pharmacological difference between the semaglutide in Ozempic and the semaglutide in Wegovy. Same active ingredient, same manufacturer, same weekly injection. Rybelsus is the third member of the family — also semaglutide, but a daily tablet.
What changes between them is the licensed indication, the dose ladder and, downstream of both, whether an insurer will pay.
What actually differs
| Ozempic | Wegovy | Rybelsus | |
|---|---|---|---|
| Licensed for | Type 2 diabetes, and cardiovascular risk reduction in type 2 diabetes | Weight management, and cardiovascular risk reduction in established CVD with obesity | Type 2 diabetes |
| Form | Weekly injection | Weekly injection | Daily tablet |
| Dose ladder | 0.25 → 0.5 → 1 → 2 mg | 0.25 → 0.5 → 1 → 1.7 → 2.4 mg | 3 → 7 → 14 mg daily |
| Maximum dose | 2 mg | 2.4 mg | 14 mg |
Notice what that ladder difference means in practice: Ozempic has no 1.7 mg step and stops at 2 mg. If you are on Ozempic for weight loss, you cannot reach the dose the weight-loss trials were run at. The titration schedule tool maps both ladders with dates.
Why the distinction costs money
Insurers price by indication, not by molecule. A plan that covers Ozempic for a diagnosed case of type 2 diabetes may not cover Wegovy for weight management, and the reverse happens too.
This is why "they're the same drug, why does it matter" is a question with a very expensive answer. The molecule is identical; the reimbursement is not. If cost is the pressure pushing you toward stopping or stretching doses, which product your plan will actually pay for is a concrete question with a concrete answer, and worth asking before improvising. The cost calculator works out what you are paying per pound lost, which makes the trade-off visible.
Ozempic for weight loss
Prescribing Ozempic for weight management is off-label. That is legal, common, and not the same as it being equivalent.
Two things follow. The dose tops out at 2 mg rather than 2.4 mg, so you cannot reach the dose used in the STEP weight-management trials or in SELECT. And insurance logic gets stranger, not simpler, because the prescription no longer matches the indication the plan is pricing.
None of that makes it a bad option — for many people it is the option that is actually available. It is just worth knowing you are on a different rung of a shorter ladder.
Common questions
- Is Ozempic the same as Wegovy?
- Same active ingredient — semaglutide, same manufacturer. They differ in licensed indication and maximum dose: Ozempic is licensed for type 2 diabetes and goes to 2 mg, Wegovy is licensed for weight management and goes to 2.4 mg.
- Which one is better for weight loss?
- Wegovy, in the narrow sense that it is the licensed product for weight management and reaches 2.4 mg — the dose the STEP weight-loss trials and the SELECT cardiovascular trial were run at. Ozempic stops at 2 mg.
- Can I switch from Ozempic to Wegovy?
- Since it is the same molecule, switching is usually simpler than moving between different drugs, but the dose you land on and whether you need to re-titrate are prescriber decisions, not automatic.
- Why won't my insurance cover Wegovy if it covers Ozempic?
- Because insurers price by licensed indication rather than by molecule. Coverage for type 2 diabetes and coverage for weight management are separate decisions even when the drug is identical.
Sources
Every figure on this page traces to one of these. Regulatory documents and peer-reviewed primary research only — see our editorial policy for what we accept as a source.
- WEGOVY (semaglutide) injection, US prescribing information. FDA, 2025. View source
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine, 2023. View source
- Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 2021. View source
- GLP-1 Agonists: What They Are, How They Work & Side Effects. Cleveland Clinic. View source
Track it whichever pen you end up with
GLPme records the product, dose and date for every shot, so a switch between brands is something you can show a clinician rather than reconstruct. Core tracking is free.
